• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld Science

BioWorld Science

July 2, 2024

View Archived Issues
mRNA on digital background

Exsilio launches with $82M to develop mRNA-based gene therapies

Exsilio Therapeutics emerged from stealth mode on June 25, 2024, with $82 million from a series A financing that was co-led by Novartis Venture Fund and Delos Capital. The company plans to use naturally occurring, mobile genetic elements to integrate therapeutic genes at a defined location in the genome, making it safer than random integration, which can cause tumor formation. Read More

Shionogi’s MGAT2 inhibitor improves metabolism in obesity models

Targeting monoacylglycerol O-acyltransferase 2 (MGAT2), an enzyme highly expressed in the small intestine, has been validated as an antiobesity strategy in the preclinical setting. Read More
3D rendering of exosomes and vesicles

Nurexone’s exosome-based therapies to be studied for regenerating damaged optic nerves

Nurexone Biologic Inc. has announced a preclinical study to explore the potential of the company’s exosome-based therapies for regenerating damaged optic nerves. The study is led by principal investigators from the Sheba Medical Center Eye Institute. Read More
Parkinsons-neurons-Lewy-bodies.png

Spur’s rationally engineered GCase85 reduces α-synuclein more effectively than wild-type GCase in vitro

Spur Therapeutics Ltd., formerly Freeline Therapeutics, has announced new data from its GBA1 Parkinson’s disease research program. In a subset of Parkinson’s disease patients with mutations in the GBA1 gene, such mutations lead to a deficiency of the glucocerebrosidase (GCase) enzyme and the accumulation of harmful substrates. Read More

Kanvas Biosciences raises funding to advance live biotherapeutic products for cancer patients

Kanvas Biosciences Inc. has raised $12.5 million in additional funding to support development of the company’s spatial biology platform and advance two novel therapeutics in its immuno-oncology program, KAN-001 and KAN-003. Read More
Viruses

Tonix awarded DTRA contract to support oral broad-spectrum antiviral program for medical countermeasures

Tonix Pharmaceuticals Holding Corp. has been awarded up to $34 million over 5 years under a contract with the U.S. Department of Defense (DoD)’s Defense Threat Reduction Agency (DTRA). Read More

Shenzhen Zhongge Biotechnology patents new IRAK-4 inhibitors

Shenzhen Zhongge Biotechnology Co. Ltd. has disclosed interleukin-1 receptor-associated kinase 4 (IRAK-4) inhibitors and/or degraders reported to be useful for the treatment of cancer, psoriasis, systemic lupus erythematosus, osteoarthritis, graft-vs.-host disease, rheumatoid arthritis, irritable bowel syndrome and chronic obstructive pulmonary disease, among others. Read More

ERRγ has oncogenic role in colorectal cancer

A group of researchers in India have looked into the role of estrogen-related receptor γ (ERRγ) in the progression of colorectal cancer (CRC), and studied the effect of combination therapy with an ERRγ inverse agonist, DN-200434, and the AKT inhibitor MK-2206 in in vitro and in vivo assays. Read More
Gastric cancer

Signet’s SIGX-1094 receives US IND clearance for diffuse gastric cancer

Signet Therapeutics Inc. has received IND clearance from the FDA for SIGX-1094 as a potential treatment for diffuse gastric cancer. A phase I trial is planned in patients with diffuse gastric cancer and other advanced solid tumors. Read More

Sichuan Kelun-Biotech Biopharmaceutical divulges new B7-H3-targeting ADCs

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has synthesized antibody-drug conjugates consisting of anti-B7-H3 antibodies covalently linked to cytotoxic drugs reported to be useful for the treatment of cancer. Read More

SK Biopharmaceuticals describes new GTPase KRAS mutant inhibitors

SK Biopharmaceuticals Co. Ltd. has identified GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer. Read More
Clinical data illustration

Medipal and JCR move JR-446 toward clinic in Japan for mucopolysaccharidosis type IIIB

Medipal Holdings Corp. and JCR Pharmaceuticals Co. Ltd. have announced the completion of the clinical trial notification review by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for a phase I/II study of JR-446 for the treatment of mucopolysaccharidosis type IIIB (MPS IIIB; Sanfilippo syndrome type B). Read More

New myeloperoxidase inhibitors disclosed in Salubris patent

Shenzhen Salubris Pharmaceuticals Co. Ltd. has divulged myeloperoxidase inhibitors reported to be useful for the treatment of cardiovascular disorders. Read More

Galectin-3 inhibitor confers protection against MASLD

Metabolic dysfunction-associated steatotic liver disease (MASLD) has a prevalence of about 25% in the adult population, with steatosis present in >5% of hepatocytes, hepatocyte ballooning and fibrosis as the main hallmarks. Scientists have tested effects of the galectin-3 inhibitor modified citrus pectin (MCP) in ApoE knockout mice fed a western diet. Read More

Pharma Foods announces autoimmune disease antibody milestone under Mitsubishi Tanabe collaboration

Pharma Foods International Co. Ltd. (PFI) has announced the achievement of a milestone under its licensing agreement with Mitsubishi Tanabe Pharma Corp. for a new investigational therapeutic antibody for autoimmune diseases. Read More

Senya Pharmaceuticals discovers new SARM1 inhibitors

Senya Pharmaceuticals Inc. has described NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors reported to be useful for the treatment of neurological disorders. Read More

Popular Stories

  • Telomeres and DNA illustration

    23andme founder-led group outbids Regeneron for company

    BioWorld
    The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...
  • Today's news in brief

    BioWorld
    BioWorld briefs for June 17, 2025.
  • Sarepta signage

    Elevidys’ second liver death hits Sarepta, sends DMD ripples

    BioWorld
    How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 17, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 17, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe